Last reviewed · How we verify
NCT06770517: DeFEAD65+
Exposure Therapy for Late-life Anxiety
NA trial testing Exposure therapy in Anxiety Disorders in 170 participants. Currently enrolling.
23 June 2028
Quick facts
| Lead sponsor | ProPersona |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 170 |
| Start date | 12 February 2025 |
| Primary completion | 23 June 2028 |
| Estimated completion | 19 December 2028 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Exposure therapy
- Usual Care
Conditions studied
- Anxiety Disorders — all drugs for Anxiety Disorders →
- Anxiety Depression — all drugs for Anxiety Depression →
Sponsor
ProPersona
Who can join
65 and older, any sex, with Anxiety Disorders or Anxiety Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective is to evaluate the (cost-)effectiveness of exposure therapy (ET) delivered by trained mental health nurses (MHNs) in terms of anxiety symptoms and quality of life for late life anxiety disorders in primary care compared to usual care (UC). UC is not restricted, and the general practitioner (GP) is encouraged to work according to the guidelines of the Dutch College of GPs. Participants in the ET group will receive 30-minute ET sessions delivered by a trained mental health nurse, during 8 sessions within the span of 12 weeks. Participants will fill in questionnaires before, during and after treatment, with a 1-year follow-up. The main study parameters are anxiety severity, quality of life and societal costs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06770517
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exposure therapy
Trials testing the same drug.
- NCT05294081 — EFFects of EXPosure and Cognitive-behavioural Therapy for Chronic BACK Pain · NA · active not recruiting
- NCT03925987 — Predicting Treatment Response to Exposure Therapy Using Carbon Dioxide · NA · completed
- NCT03206996 — Exposure Therapy for Auditory Sensitivity in Autism · NA · completed
- NCT03233113 — The Effects of Safety Seeking Behaviors During Exposure Therapy for Adults With Spider Phobia · NA · completed
- NCT03174249 — Exposure Therapy Combined With Cortical Interventions for CRPS-II · NA · completed
Other recruiting trials for Anxiety Disorders
Currently open trials in the same condition.
- NCT07340281 — Biomarkers for Exercise · NA · recruiting
- NCT07432945 — In Vivo Exposure vs. Videochat-Based Vicarious Exposure · NA · recruiting
- NCT07316374 — AI Chatbots for Anxiety Mental Health Literacy · NA · active not recruiting
- NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
- NCT07174947 — SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depre · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06770517 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ProPersona
- Last refreshed: 29 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06770517.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing